SOTIO® is a biotechnology company developing innovative therapies that harness the immune system and focus primarily on immuno-oncology, effectively translating science into patient benefit. SOTIO® is owned by the PPF Group, one of the largest investment groups in Central and Eastern Europe.

The most advanced project is proprietary platform of active cellular immunotherapy (ACI) based on dendritic cells for the treatment of cancer and autoimmune diseases. SOTIO® is conducting multiple Phase I to Phase III clinical trials verifying the safety and efficacy of its DCVAC products.

Through agreements with Cytune Pharma, NBE-Therapeutics and Lead Discovery Center, SOTIO® has added more novel oncology programs to its pipeline. We collaborate together to advance these programs to the clinical development stage and towards commercialization.

BD section is ready to launch!

SOTIO, a biotechnology company owned by the PPF Group,
today announced that it will present an abstract highlighting
the design, methods and objectives of its
VIABLE study.

Clinical Trials

Prostate Cancer

Phase II Clinical Trials of DCVAC/PCa - besides Phase III VIABLE study we have initiated five Phase II clinical trials for patients with prostate cancer at various stages of the disease. Recently launched SP015 clinical trial evaluating combination of DCVAC/PCa and ONCOS-102, an immune-priming adenovirus, is currently enrolling patients in the Czech Republic.

Ovarian Cancer

Phase II Clinical Trials of DCVAC/OvCa - four Phase II clinical trials have been launched to assess the effect of addition of DCVAC platform (DCVAC/OvCa) to standard of care chemotherapy in patients with ovarian cancer at various stages of the disease. DCVAC/OvCa clinical trials have been conducted at medical centers in the Czech Republic, Germany and Poland. SOV01 and SOV06 clinical trials are currently enrolling patients with epithelial ovarian cancer.

Lung Cancer

Phase I/II Clinical Trial DCVAC/LuCa - SLU01 study was launched to assess the use of DCVAC platform (DCVAC/LuCa) combined with standard treatments in patients with advanced lung cancer. This clinical trial recruited patients at medical centers in the Czech Republic and Slovakia and is currently in the phase of final evaluation.

Další informace o aktivní buněčné imunoterapii, která se zaměřuje na léčbu onemocnění rakoviny.

Contacts

Boston
Boston
SOTIO LLC
180 Canal St,
Suite 300
Boston, MA 02114
USA
CONTACT
Praha
Praha
SOTIO a.s.
Jankovcova 1518/2
170 00 Praha 7
Česká republika
CONTACT
Moskva
Moskva
SOTIO LLC
Pravdy Street, 8,
blok 1 (8. patro)
Moskva 125040
Ruská federace
CONTACT
Peking
Peking
SOTIO Medical Research (Beijing) Co., Ltd.
Beijing Economic - Technological Dev. Area
99 Kechuang 14, 30-B
Beijing 100176
China
CONTACT
Tento web používá k poskytování služeb, personalizaci reklam a analýze návštěvnosti soubory cookie. Používáním tohoto webu s tím souhlasíte. Další informace